The Bridging Effect of Controlled-Release Glial Cell-Derived Neurotrophic Factor Microcapsules within Nerve Conduits on Rat Facial Nerve Regeneration

Siwen Xia,Mingxing Zhang,Meng Li,Xianmin Song,Donghui Chen,Minhui Zhu,Hongliang Zheng,Shicai Chen
DOI: https://doi.org/10.1155/2022/8942985
2022-06-21
Disease Markers
Abstract:Objectives. The study is aimed at exploring the effect of the controlled release of the glial-derived neurotrophic factor (GDNF) on nerve regeneration. Methods. The PLGA/chitosan composite nerve conduit was used to bridge the dissected trunk of the rat facial nerve. GDNF microcapsules were loaded into the nerve conduit. Nine weeks after surgery, the facial nerve zygomatic and buccal branches were labeled with fluorescent indicators. The incorrectly grown facial neurons were reversed and counted. The facial nerve functional recovery was assessed by measuring the maximum evoked potential. Results. The nerve conduit was filled with different regenerating factors, such as the GDNF, GDNF microcapsules, or saline (control). The number of incorrectly regenerated neurons was lower with the nerve conduits filled with GDNF microcapsules than with those supplied with just the GDNF. However, neither the GDNF nor GDNF microcapsules affected the number of regenerated neurons. The functional recovery of the facial nerve was the best, with the nerve conduit filled with GDNF microcapsules closest to the healthy uncut facial nerve. Conclusion. The stable slow-release GNDF microcapsule inside the biodegradable nerve conduit can reduce the extent of incorrect growth of the facial nerve neuron when bridging the dissected rat facial nerve trunk. The technique has a good effect on functional nerve recovery.
genetics & heredity,pathology,medicine, research & experimental,biotechnology & applied microbiology
What problem does this paper attempt to address?
This paper attempts to address the issue of reducing the number of misregenerated neurons and improving the recovery of facial nerve function during facial nerve regeneration by controlling the release of glial cell line-derived neurotrophic factor (GDNF). Specifically, the researchers designed a PLGA/chitosan composite nerve conduit, loading GDNF microcapsules into the conduit to bridge the severed ends of the rat facial nerve. Through this method, they hope to achieve stable sustained release of GDNF, thereby promoting nerve regeneration and reducing the phenomenon of misregeneration. The main objectives of the study include: 1. **Exploring the effect of sustained release of GDNF on nerve regeneration**: By loading GDNF microcapsules into the nerve conduit, observing its impact on facial nerve regeneration. 2. **Evaluating nerve function recovery**: Assessing the recovery of facial nerve function by measuring the maximum evoked potential. 3. **Reducing misregeneration**: Evaluating whether the sustained release of GDNF can reduce the number of misregenerated neurons by fluorescent labeling and counting misgrown facial neurons. The results of the study indicate that compared to the use of GDNF alone or the control group, the nerve conduit with GDNF microcapsules significantly reduced the number of misregenerated neurons and showed the best performance in functional recovery, approaching that of healthy, undamaged facial nerves. These findings provide an experimental basis for future treatments aimed at the recovery of facial nerve function and lay the groundwork for the clinical application of this technology.